UROGEN PHARMA LTD
1 day chart
Kickstart your portfolio with a U.S. stock on us
Sign up and fund a new Wall St account and get a full share randomly chosen between GoPro, Dropbox or Nike.
Sign up and fund a new Wall St account and get a full U.S. share.
T&Cs apply
About URGN
UroGen Pharma Ltd. Is an Israel-based biopharmaceutical company. The Company is engaged in building solutions for cancers and urologic diseases. UroGen has developed RTGelTM reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. Its lead product candidates include MitoGel and VesiGel are formulated using its proprietary reverse thermally triggered hydrogel, or RTGel, technology. MiroGel ( UGN-101) is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract. VesiGel (UGN-102) is a sustained release formulation of a high dose Mitomycin C for the treatment of low grade non-muscle invasive bladder cancer (LG-NMIBC).
Find out what a historical investment in UROGEN PHARMA LTD would be worth today using our URGN stock calculator.
$337.05M
-
0.00%
9.68M
$8.75
$6.46
$8.75
$20.70
$8.94
Ready to start your investing journey with Stake?
Open an accountURGN FAQs
- Sign up with some I.D. and zero paperwork
- Add funds to your account
- Make your first investment in URGN
This is not financial product advice nor a recommendation to invest in the securities listed. Past performance is not a reliable indicator of future performance. As always, do your own research and consider seeking financial, legal and taxation advice before investing. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.
Invest in URGN
on Stake
Buy URGN from US$3 brokerage
Invest in 9,500+ U.S. stocks and ETFs
Own a slice of URGN from only US$10 with fractional shares
